Last updated: August 31, 2026
Novartis Pharmaceuticals Corporation sued Par Pharmaceutical, Inc. in the U.S. District Court for the District of Delaware after Par submitted an Abbreviated New Drug Application seeking approval for a generic version of Votrient, Novartis's pazopanib hydrochloride product. The case was a Hatch-Waxman patent dispute centered on U.S. Patent No. 8,410,131, which covered pazopanib compounds and their use in treating cancer.
The litigation did not produce a reported merits decision invalidating the patent. The case was resolved through a negotiated disposition rather than a public trial judgment. The principal commercial issue was whether Par could launch generic pazopanib before the expiration of Novartis's patent rights and, if so, under what settlement terms.
What drug and patents were involved in Novartis v. Par?
The case involved Votrient, whose active ingredient is pazopanib hydrochloride. Votrient is an oral tyrosine kinase inhibitor approved by the FDA for certain patients with advanced renal cell carcinoma and advanced soft-tissue sarcoma.
| Item |
Detail |
| Branded product |
Votrient |
| Active ingredient |
Pazopanib hydrochloride |
| Innovator |
Novartis Pharmaceuticals Corporation |
| Generic applicant |
Par Pharmaceutical, Inc. |
| FDA pathway |
ANDA under the Hatch-Waxman Act |
| Court |
U.S. District Court for the District of Delaware |
| Case number |
1:15-cv-00078 |
| Primary patent |
U.S. Patent No. 8,410,131 |
| Patent subject matter |
Pazopanib compounds and pharmaceutical uses |
| Litigation type |
ANDA patent infringement action |
| Filing period |
January 2015 |
| Public resolution |
Negotiated dismissal rather than a reported trial judgment |
The dispute arose from Par's certification to the FDA concerning Novartis's Orange Book-listed patent. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. Novartis responded by filing an infringement action within the statutory period.
What patent protected Votrient in the case?
The principal patent was U.S. Patent No. 8,410,131, assigned to Novartis. The patent covered chemical compounds in the pazopanib family and related pharmaceutical applications.
The '131 patent was commercially significant because it extended patent protection beyond the basic discovery of a kinase inhibitor. Its asserted scope included the active compound and its use in oncology treatment. That structure allowed Novartis to challenge an ANDA applicant even if the applicant did not copy the branded product's trade dress, manufacturing process, or proprietary formulation.
The patent's ordinary expiration date was in 2027, subject to any applicable patent-term adjustment or extension. The patent was therefore capable of delaying generic pazopanib competition well beyond the expiration of Votrient's initial regulatory exclusivity.
How strong was the Votrient patent estate?
The estate was materially stronger than a single narrow formulation patent because the '131 patent addressed the active pharmaceutical ingredient and therapeutic use. A compound patent generally presents a larger infringement barrier than a patent limited to tablet composition, particle size, dissolution profile, or manufacturing parameters.
The principal vulnerabilities were:
- Obviousness based on earlier kinase-inhibitor disclosures.
- Whether the prior art provided a reason to select pazopanib from a broad chemical genus.
- Whether the prior art created a reasonable expectation of achieving the claimed kinase activity and clinical utility.
- Claim-construction disputes concerning the chemical and therapeutic scope of the asserted claims.
- Potential differences between the proposed generic label and the patented methods of use.
The later Federal Circuit litigation involving other Votrient generic applicants treated the '131 patent as a substantial patent barrier. In Novartis Pharmaceuticals Corp. v. West-Ward Pharmaceuticals International Ltd., the Federal Circuit affirmed the nonobviousness of asserted claims directed to pazopanib, reinforcing the value of the patent for generic-entry analysis.[4]
Why did Novartis sue Par under Paragraph IV?
A Paragraph IV filing creates a statutory basis for patent litigation before FDA approval of the ANDA. Once the brand company receives notice, it may sue within 45 days. A timely suit generally triggers an automatic FDA approval stay of up to 30 months, unless the court resolves the case earlier or another statutory exception applies.[2]
Novartis's complaint alleged that Par's proposed generic pazopanib product would infringe one or more claims of the '131 patent. The case was therefore designed to establish a pre-approval infringement judgment and preserve the patent-based regulatory stay.
The core legal questions were:
- Whether Par's ANDA product would infringe the asserted claims.
- Whether Par's Paragraph IV invalidity defenses were legally and factually sufficient.
- Whether the asserted claims were obvious in view of earlier kinase-inhibitor patents and publications.
- Whether the proposed generic labeling induced infringement of patented therapeutic uses.
- Whether any noninfringement position depended on a carve-out from the FDA-approved label.
What was the procedural history?
The case was filed in the District of Delaware in January 2015. As with most ANDA cases, the complaint was based on the content of Par's ANDA and its Paragraph IV notice rather than on commercial sales of an approved generic product.
Litigation timeline
| Date or period |
Event |
| January 2015 |
Novartis filed the patent infringement complaint against Par. |
| 2015 |
Par asserted invalidity and noninfringement defenses in response to the ANDA-based claims. |
| 2015-2016 |
The parties litigated claim scope, infringement, validity, and discovery issues. |
| Resolution period |
The case ended through a negotiated disposition and dismissal rather than a reported merits trial. |
| 2027 |
Expected ordinary expiration period for the principal '131 patent, subject to statutory adjustments. |
The public docket does not provide a reported claim-construction ruling, bench-trial opinion, or final judgment holding the '131 patent invalid. The absence of a merits opinion means the case did not create binding Delaware precedent resolving Par's specific product design or defenses.
Did Par win or lose the patent case?
The docket outcome should not be characterized as a merits victory for either party. The action ended without a publicly reported adjudication that Par's ANDA infringed, or that the patent was invalid or unenforceable.
The practical result was a settlement-based resolution. In Hatch-Waxman matters, a dismissal after settlement usually reflects an agreement concerning generic launch timing and related commercial terms. The specific settlement terms are often confidential. A docket dismissal alone does not establish:
- An agreed early-entry date.
- A finding that the patent was valid.
- A finding that the generic product infringed.
- A finding that Par's Paragraph IV position was legally incorrect.
- A determination that the patent would survive a full validity trial.
What was the commercial effect of the litigation?
The case protected the timing of generic pazopanib entry during a period when Votrient remained a significant oncology product. Novartis's economic exposure included:
- Loss of branded pazopanib sales after generic launch.
- Price erosion from multiple generic suppliers.
- Formulary substitution and pharmacy-level generic substitution.
- Reduced negotiating leverage with hospitals and oncology practices.
- Potential erosion of follow-on pazopanib revenue before the 2027 patent date.
The settlement gave Novartis a mechanism to control the timing of Par's market entry without assuming the litigation risk of a validity trial. For Par, settlement reduced the risk of an adverse infringement judgment and eliminated the costs and delay associated with a full trial.
The settlement's commercial value depended on whether Par received a first-filer position, an agreed launch date, or other consideration. Those terms were not publicly disclosed in the case record.
Did the case affect FDA approval or Orange Book status?
The litigation was linked to an ANDA and a Paragraph IV certification, so it affected the timing of FDA approval under the Hatch-Waxman framework. The suit also implicated the statutory 30-month stay that can delay FDA approval after timely patent litigation.
The case did not remove the '131 patent from the Orange Book. The FDA's Orange Book function is to identify patents submitted by the NDA holder for approved products. Patent validity and infringement are determined by the courts, not by the FDA.[3]
The FDA approval consequences were therefore procedural:
- Par could not obtain unrestricted final approval while the statutory litigation stay remained operative, unless the stay was terminated or otherwise resolved.
- A settlement could establish a contractual launch date before patent expiration.
- The FDA could approve the ANDA after the applicable litigation and exclusivity barriers expired.
- The existence of the case did not itself prove that the generic was unapprovable on safety or efficacy grounds.
What generic-entry risks existed after settlement?
The main generic-entry scenarios were as follows.
Agreed early launch
Par could enter before the ordinary patent expiration date if Novartis granted a license or agreed not to enforce the patent before a specified date. This is the most commercially important settlement variable.
Entry after patent expiration
If the settlement did not authorize an earlier launch, Par would remain blocked until the '131 patent and any applicable pediatric or other statutory extension expired.
Earlier entry after patent invalidation by another defendant
A judgment in favor of another generic applicant could weaken Novartis's ability to enforce the same patent against Par. The later West-Ward Votrient litigation reduced that risk by upholding the central patent claims.[4]
Launch after a label carve-out
A generic applicant could attempt to remove patented indications from its labeling under the section viii procedure. That strategy depends on whether the remaining label avoids inducing infringement and whether the FDA accepts the proposed carve-out.[2]
At-risk launch
Par could have launched before final resolution at the risk of damages and injunctive relief. This scenario was commercially unattractive where the asserted patent covered the active compound itself.
How did this case compare with other Votrient patent litigation?
Novartis's dispute with Par was part of a broader generic-challenge landscape involving pazopanib. The commercial value of the case was tied to the same core patent estate later tested in other ANDA proceedings.
| Issue |
Novartis v. Par |
Later Votrient litigation |
| Product |
Votrient |
Votrient |
| Active ingredient |
Pazopanib hydrochloride |
Pazopanib hydrochloride |
| Core patent |
U.S. Patent No. 8,410,131 |
U.S. Patent No. 8,410,131 |
| Legal posture |
ANDA litigation and negotiated resolution |
Merits litigation producing appellate precedent |
| Public merits ruling |
No reported trial judgment |
Federal Circuit affirmed nonobviousness |
| Generic risk |
Controlled by settlement terms |
Reduced by appellate confirmation of patent validity |
The comparison matters because a private settlement does not resolve the general strength of an innovator's patent. The Federal Circuit's later ruling supplied the stronger public evidence that the core Votrient patent could withstand an obviousness challenge.[4]
What litigation and licensing information is public?
The public record identifies the complaint, the parties, the patent dispute, and the case disposition. It does not disclose the complete economic terms of the settlement.
No public record in the case establishes:
- A royalty rate.
- An authorized-generic arrangement.
- A supply agreement.
- A co-promotion right.
- A specific Par launch date.
- A payment amount.
- A covenant covering patents outside the asserted case.
The settlement should therefore be analyzed as a timing and risk-allocation event, not as evidence of a broad Novartis-Par commercial alliance.
What is the current patent and exclusivity outlook for Votrient?
Votrient's initial FDA approval exclusivity is distinct from patent protection. Regulatory exclusivity expires under FDA rules based on the approval date and product classification, while patent protection depends on the listed patents and statutory extensions.[3]
For commercial forecasting, the '131 patent was the principal barrier identified in the case. The ordinary patent expiration period extended into 2027, making the settlement's agreed launch terms more important than the nominal FDA exclusivity period.
Biosimilar risk was not relevant. Pazopanib is a small-molecule drug regulated through the ANDA pathway. Competitive risk comes from chemically equivalent generic tablets, not from biosimilar versions under the Public Health Service Act.
Key Takeaways
- Novartis sued Par in the District of Delaware over an ANDA for generic Votrient, or pazopanib hydrochloride.
- The central patent was U.S. Patent No. 8,410,131.
- The case was a Paragraph IV Hatch-Waxman action.
- The public docket does not show a merits judgment invalidating the patent or finding Par's product infringing.
- The case ended through a negotiated disposition and dismissal.
- Settlement terms, including any agreed generic launch date, were not publicly disclosed.
- The later Federal Circuit decision in related Votrient litigation upheld the nonobviousness of the '131 patent.
- Biosimilar exposure was not relevant because pazopanib is a small-molecule ANDA product.
- The principal commercial variable was the timing of Par's generic launch relative to the patent's 2027 expiration period.
FAQs About Novartis v. Par Pharmaceutical
What was the drug in Novartis Pharmaceuticals Corp. v. Par Pharmaceutical?
The case concerned Votrient, the brand-name product containing pazopanib hydrochloride, an oral oncology tyrosine kinase inhibitor.
What patent did Novartis assert against Par?
Novartis primarily asserted U.S. Patent No. 8,410,131, which covered pazopanib-related compounds and therapeutic uses.
Was Par's generic pazopanib approved by the FDA?
The patent case itself does not establish the date of FDA approval or commercial launch. FDA approval timing was affected by the Paragraph IV litigation and any settlement-based restrictions.
Did Novartis and Par publicly disclose their settlement terms?
No. The public case record does not disclose the economic terms, royalty provisions, or precise generic launch date.
Does the case create a precedent on pazopanib patent validity?
No direct merits precedent arose from the Par case. The more important public precedent came from related Votrient litigation in which the Federal Circuit affirmed the validity of asserted claims of the '131 patent.
References
-
U.S. District Court for the District of Delaware. (2015). Novartis Pharmaceuticals Corporation v. Par Pharmaceutical, Inc., No. 1:15-cv-00078.
-
21 U.S.C. § 355(j) (2023).
-
U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations (Orange Book).
-
Novartis Pharmaceuticals Corp. v. West-Ward Pharmaceuticals International Ltd., 923 F.3d 1051 (Fed. Cir. 2019).
